- Home
- BUD vs AZN Comparison
BUD vs AZN Comparison
Compare BUD & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BUD | AZN |
|---|---|---|
| Founded | 1366 | 1992 |
| Country | Belgium | United Kingdom |
| Employees | 136805 | 96100 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.7B | 316.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BUD | AZN |
|---|---|---|
| Price | $78.27 | $185.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $92.00 | N/A |
| AVG Volume (30 Days) | 1.4M | ★ 1.7M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | 1.33% | ★ 1.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.01 | $10.34 |
| Revenue Next Year | $3.67 | $6.43 |
| P/E Ratio | ★ $23.27 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $56.97 | $68.62 |
| 52 Week High | $84.46 | $212.71 |
Technical Indicators
Market Signals| Indicator | BUD | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 49.81 |
| Support Level | $60.04 | $180.98 |
| Resistance Level | $82.01 | $191.50 |
| Average True Range (ATR) | 1.12 | 3.00 |
| MACD | -0.76 | -0.05 |
| Stochastic Oscillator | 9.51 | 61.27 |
Price Performance
Historical ComparisonAbout BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium)
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. The company's portfolio contains six of the top 10 beer brands by volume, and we estimate it distributes 23 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and US-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev, an 87% stake in Budweiser APAC, and in 2016 it acquired SABMiller.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.